Endomines releases its H2/24 results on 13th of February.
F&MT initiates cost-cutting program Gradual recovery expected Q4 due on 10 February Q4e: Organic sa...
On February 4thth, Eevia Health Plc (publ) (“Eevia”) announced that the Company has agreed to sell I...
Redeye shares its initial thoughts on CTEK’s Q4 report.
Redeye provides its initial take on Vitec’s Q4 2024 report, which featured sales that clearly exceed...
Redeye comments on the Q4 report released earlier this morning.
Redeye returns with a more in-depth take on OssDsign’s Q4 report.
Navamedic ASA (”Navamedic” or ”the Company”) is a Nordic pharmaceutical company offering a diversifi...
Q4 a tad soft at 5% organic growth and EBIT -6% But the undelrying business appears in very good sha...
Sales and gross margin above expectations in Q4 EBIT revised up by 2.
Kingspan bids SEK 182.5/shareNWG's board recommends accepting the bidHighly likely the bid will go t...
Redeye provides initial comments on Sleep Cycle’s Q4 report, in which sales were in line with expect...
Den 3 februari 2025 meddelade AcuCort (”AcuCort” eller ”Bolaget”) utfallet i företrädesemissionen, v...
Raute reports Q4 results on Feb 13. FY’24 already showed strong results, while low valuation limits ...
Beat in Q4 driven by higher sales EBIT +7% vs ABGSCe Estimates likely to be revised up 2-5% on EBIT ...
Etteplan reports its Q4 figures on 12th of February.
Redeye initiates coverage of Corline Biomedical, a Swedish medtech/biotech company specialising in c...
Ahead of Taaleri's Q4 results, we revise our underlying estimates to reflect Taaleri's sale of its s...
DT reports Q4 results on Feb 6. We make limited estimate revisions ahead of the report as outlook re...
Consti reports its Q4 result on 7th of February. We anticipate slight sales growth for Q4, although ...
